Ginkgo Bioworks (NYSE:DNA) Trading Up 8.8%

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) shot up 8.8% during mid-day trading on Tuesday . The company traded as high as $3.96 and last traded at $3.95. 202,744 shares were traded during trading, a decline of 99% from the average session volume of 16,536,961 shares. The stock had previously closed at $3.63.

Several research analysts have weighed in on DNA shares. BTIG Research lowered their price target on shares of Ginkgo Bioworks from $12.00 to $6.00 in a report on Thursday, March 31st. Raymond James cut their price target on shares of Ginkgo Bioworks from $14.50 to $11.50 and set an “outperform” rating on the stock in a report on Tuesday, April 5th. Zacks Investment Research lowered shares of Ginkgo Bioworks from a “buy” rating to a “hold” rating in a report on Monday, April 4th. Cowen initiated coverage on shares of Ginkgo Bioworks in a report on Wednesday, March 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Finally, Bank of America reissued a “neutral” rating and set a $6.00 target price on shares of Ginkgo Bioworks in a research note on Tuesday, February 1st. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.82.

The firm has a fifty day moving average price of $3.96 and a 200-day moving average price of $7.96. The company has a quick ratio of 12.76, a current ratio of 12.79 and a debt-to-equity ratio of 0.01.

Ginkgo Bioworks (NYSE:DNA – Get Rating) last released its quarterly earnings data on Monday, March 28th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.95). On average, analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.13 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Close Asset Management Ltd bought a new stake in Ginkgo Bioworks during the 3rd quarter valued at $25,000. Van ECK Associates Corp bought a new stake in Ginkgo Bioworks during the 4th quarter valued at $35,000. Endurance Wealth Management Inc. increased its holdings in shares of Ginkgo Bioworks by 150.0% in the fourth quarter. Endurance Wealth Management Inc. now owns 5,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares during the period. US Bancorp DE bought a new position in shares of Ginkgo Bioworks in the third quarter worth $93,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Ginkgo Bioworks in the third quarter worth $116,000.

Ginkgo Bioworks Company Profile (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Read More